| Journal: |
J Cardiovasc Pharmacol
international
|
Volume: |
|
| Abstract: |
Myocardial infarction is among the leading causes of
mortality. Menaquinone-4 (MK-4), a vitamin K2 analog, might play a
role in rescuing cardiac ischemia/reperfusion (I/R) injury. This work
aimed to discover the potential cardioprotective role of MK-4 against
myocardial I/R injury in rats. Thirty-two rats were categorized into 3
groups: (I/R) control group: subjected to I/R protocol (received
vehicle), MK-4 preconditioning group: MK-4 infusion for 20 minutes
before the I/R protocol, and MK-4 postconditioning group: MK-4
infusion for 20 minutes at the start of the reperfusion phase. The hearts
were placed in the Langendorff apparatus, and the left ventricular
developed pressure (LVDP), heart rate (HR), + (LV dP/dt) max, 2
(LV dP/dt) max, and Tau were calculated. The necrotic mass was
determined by staining it with nitro blue tetrazolium. Creatine
kinase-MB (CK-MB), lactate dehydrogenase (LDH), tumor necrosis
factor-a (TNF-a), interleukin-6 (IL-6), and C- reactive protein (CRP),
as well as cardiac superoxide dismutase (SOD), nitric oxide (NOx),
malondialdehyde (MDA), and glutathione (GSH) levels were all evaluated.
MK-4 postconditioning significantly reduced myocardial infarct
size; increased LVDP, + (LV dp/dt) max, 2 (LV dp/dt) max, and HR;
reduced Tau, CK-MB, LDH, CRP, IL-6, TNF-a, MDA, and NOx
levels; and increased SOD activity, whereas no significant difference
in the GSH level was detected. In conclusion, these data imply that
MK-4 may protect the heart from the consequences of I/R.
|
|
|